 BOSTON, Feb. 10, 2021 GLOBE NEWSWIRE -- Rhythm Pharmaceuticals, Inc. Nasdaq: RYTM, a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic diseases of obesity, today announced the closing of its public offering of 5,750,000 shares of its common stock at a public offering price of 30.00 per share, which includes the exercise in full by the underwriters of their option to purchase up to an additional 750,000 shares of common stock, on February 9, 2021. The aggregate gross proceeds to Rhythm from the offering were approximately 172.5 million, before underwriting discounts, commissions, and offering expenses. All of the shares in the offering were offered by Rhythm. 